Cipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Above 50 Day Moving Average of $2.27

Cipher Pharmaceuticals Inc. (TSE:CPHGet Rating) (NASDAQ:CPHR) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$2.27 and traded as high as C$2.27. Cipher Pharmaceuticals shares last traded at C$2.27, with a volume of 13,300 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Echelon Wealth Partners restated a “buy” rating on shares of Cipher Pharmaceuticals in a research note on Friday, May 13th.

Cipher Pharmaceuticals Stock Down 0.9 %

The business’s fifty day moving average price is C$2.27 and its 200 day moving average price is C$2.22. The company has a quick ratio of 2.25, a current ratio of 2.42 and a debt-to-equity ratio of 1.30. The firm has a market capitalization of C$57.21 million and a PE ratio of 5.49.

Cipher Pharmaceuticals (TSE:CPHGet Rating) (NASDAQ:CPHR) last announced its earnings results on Thursday, May 12th. The company reported C$0.08 EPS for the quarter. The business had revenue of C$4.97 million during the quarter, compared to analysts’ expectations of C$7.18 million. On average, equities research analysts forecast that Cipher Pharmaceuticals Inc. will post 0.5 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

(Get Rating)

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug.

Recommended Stories

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.